Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Bosentan Hydrate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Zydus Receives Tentative Approval from The USFDA for Bosentan Tablets for Oral Suspension
Details : Bosentan is a specific and competitive antagonist at endothelin receptor types ETA and ETB. It is developed for for the treatment of PAH in pediatric patients aged 3 years and older with idiopathic or congenial PAH to improve pulmonary vascular resistanc...
Brand Name : Bosentan-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 15, 2023
Lead Product(s) : Bosentan Hydrate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?